Okay. Good morning, everybody. Good afternoon. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce Monte Rosa Therapeutics. We have with us Markus Warmuth, Chief Executive Officer. Great to see you, Markus. Thank you so much for joining us.
Yeah, great to see you, and thanks for inviting us to your conference here.
Yeah, absolutely. To start with, would you like to give a brief overview of the company and of your QuEEN molecular glue degrader platform for those who may be newer to the story, and then we can get into some Q&A?
Yeah, no, happy to. Monte Rosa, still a fairly young company. We're about seven years old now. You can tell from the name, we originated in Switzerland, although we're now headquartered in the U.S. We're doing targeted protein degradation. As you know, there's different ways of doing it. There's a modality called PROTACs. That's what we're not doing, sort of heterobifunctional molecules that bind to the protein destruction complex and something you want to destroy. Our molecules are a bit more complex, although they're technically smaller. They're small molecules that essentially bind to a ubiquitin ligase, which is part of that protein destruction complex, and reshape its surface to induce a protein-protein interaction with the target we want to get rid of. For us, it really opened up a lot of opportunities around targets that others are just flat out not able to go after.
VAV1, which we probably will touch on, is one of the best examples for them.
Great. I wanted to start with MRT-8102, which is your wholly owned NEK7 degrader. Moving into phase II. Just to start with, when you think about NEK7 degradation versus direct NLRP3 inhibition, what are the key advantages of your approach, and are you aiming to achieve better efficacy or safety, or?
Yeah, we are now in the NLRP3 inflammasome, which obviously is a hot pathway, also a contested one, which I am sure we will talk about in a second. There are two ways you can inhibit the NLRP3 inflammasome. You have a direct inhibitor, or, as in our case, a NEK7 degrader. What does a NEK7 degrader, 8102, do? NEK7 actually is an essential scaffolding protein for the NLRP3 inflammasome. Essentially, there is no NEK7, there is no active, fully assembled inflammasome, and we like that, of course, better than the on and off inhibition that you get with inhibitors. We also think that provides for better safety margins, because we can make our degraders exquisitely selective, and we can actually test it on a cellular level through proteomics. We know that 8102 degrades NEK7 and nothing else across multiple different cell types we have tested.
For NLRP3 inhibitors, best case, you have some other ATPase biochemical assays, but you really can test selectivity across 10,000, 20,000 proteins in a cell. We are super confident in general when we go into the clinic about the level of selectivity, and then, of course, also safety. The last point to make is, when you degrade, the protein is gone, the pathway is shut down, it does not necessarily typically not come back. You do get much deeper, more prolonged PD, which obviously we think will translate into better efficacy.
Great. Very topical is the ZEUS dataset. There was recently at AHA the full dataset from Novo Nordisk with their IL-6 program, which was very relevant to you guys in the broader NLRP3 space as well. It would be interesting to hear your perspective on that and the implications for upstream approaches, including your approach. Yeah.
Yeah. I mean, obviously, ZEUS and the data release sent shockwaves through the fields. I will always remember the date was July 31st. That is how dramatic this was for us. That said, true, we were always a little skeptical around the IL-6 targeting. If you think about the pathway, the NLRP3 pathway, IL-6 is very far downstream. It is literally the last step before you essentially synthesize and release CRP from the liver, and it was unclear to us how that feeds back into active inflammation in atherosclerotic plaques. A week or two after the actual data was presented at AHA, I think it became, or is even more clear why the trial did not succeed, and I think it is really a combination of what I just said, maybe not the best target to go after, plus maybe not the best drug.
It was interesting to see that the antibody left about 25% IL-6 in the system. It reduced IL-6 levels by 75%. I would have expected 90% and greater for an antibody. There were clearly some issues around, actually not some big issues around the trial design. I think there was an obsession around selecting for high CRP levels. Probably that led to the idea of selecting patients with chronic kidney disease, CKD. That alone actually, of course, increases your CRP levels. Many of the patients, the majority, vast majority were obese, so you now have inflammation coming from the liver. Of course, when you end up with a CRP level of greater than 3 mg/L , now you do not know, okay, how much is from the kidney, from the liver, or an active atherosclerotic plaque.
Many of the patients going into this trial might not even have had an ongoing ASCVD issue. I think between these three things, probably not a shocker that the trial was negative, which translates into we still have very, very high conviction around the pathway, the level of validation between increased lipids, oxidized LDL, oxidized cholesterol, and triggering the NLRP3 pathways rock solid. I think if you have the right trial design, you really find the patients that still have remaining inflammatory risk in ASCVD, you will be absolutely successful.
After AHA, I know there was also some conversation about this at ESC. Do you feel like industry and physician community are kind of coming round to the idea that NLRP3 and then NEK7 should be interrogated as the next targets? Or is that kind of slower moving?
Yeah, no, it feels that way. To be honest, I mean, even post-ZEUS, I understand why, right? I think investors reacted like, "Okay, it's over," right? Like, inflammation has been invalidated. We never had that feeling, that negativity, talking to our KOLs, or even the strategics we interact with on a fairly regular basis. I think everyone just came to the conclusion, okay, IL-6, maybe not the right target. Also, some pharma companies are even still hanging on to that. But if you do go upstream, this should eventually be working. I think the best document for that is, since ZEUS, I think Novartis started a phase II trial in ASCVD with their next generation NLRP3 inhibitor. Roche has now started one with their next generation NLRP3 inhibitor.
Novo actually has started a phase I with an NLRP3 inhibitor, obviously with an intention to then go into a phase II. It's unclear yet what Lilly will do with the Ventyx asset, but they're probably also going to land at some point somewhere between metabolic disease and ASCVD. I think the conviction in strategics around the pathway and targeting upstream is extremely high, as high as ours.
They're getting it. I think investors are wondering what is the next kind of catalyst in this? What is the next important development in the NLRP3, NEK7, space in cardiovascular disease? Is it going to be a pharma company starting a cardiovascular outcomes trial? Is it going to be something else? What are your thoughts on that?
Well, hopefully at our GFORCE-2 study, when it delivers a clear context for how this could work. Obviously, in GFORCE-1, we had also somewhat simplified the population we were going after. But keep in mind, that wasn't a cardiovascular outcome study, right? There was a phase I SAD/MAD safety PK/PD study. What we are now trying to do in our phase II is really within coronary artery disease, so probably the most important subgroup of ASCVD, establish a correlation between inflamed atherosclerotic plaques determined by imaging, and then the types of biomarkers we can modulate, and genetics, because there's really also very strong genetics around the NLRP3 inflammasome. I do think pharma companies also going down the path and starting phase IIIs can certainly help with the conviction around the pathway as well.
Mm-hmm. Why don't we talk a bit then about your recent GFORCE-1 data and why that was interesting, and the additional biomarkers that you showed there as well. Then we can talk about your GFORCE-2 trial as well in more detail.
Yeah, I mean, as I said, GFORCE-1, sort of a, I was about to say classical phase I study, but it really wasn't because it was more than SAD/MAD, right? We've added this sort of extended four-week cohort with the subjects at risk of developing cardiovascular disease. The way to find these obviously was to look for obese patients, which now is sort of a little bit contradictory to, like I was trashing Novo for selecting too many obese. But again, for us, it was mostly just finding a population where biomarkers were elevated to a point where we could show within four weeks that we could bring them down. I think the most important difference to what many others have done is we went way broader in biomarkers, right? Because sure, and I still think CRP is a great biomarker. It's not a causal biomarker though, right?
Sometimes you will bring it down and it's like, doesn't matter, and then sometimes you bring it down, but you've hit the right node and it actually does matter. But we went much broader. We were focused quite a bit on what's called DAMPs. So these are more local mediators of inflammation. Many of these actually have been shown to be down-modulated in ASCVD by lipid-lowering drugs as well, as inflammation goes away. Probably some of the best known are calprotectin and HMGB1. For each of these, we were actually able to show that they basically go back to normal physiological levels. So, really encouraging. Obviously, in that study, we haven't used imaging yet for atherosclerotic plaques. Probably also wouldn't have made much sense, right? Because within four weeks, it's harder to expect to see any meaningful differences by imaging.
But yeah, we were certainly extremely pleased with the outcome. Also worth mentioning that in this study, we dosed between 5 mg and 40 mg, and we saw similar levels of biomarker modulation between these different cohorts. So, essentially establishing a pretty wide range of doses that we can now work with.
Great. And with GFORCE-2, I know you're not the only company to go into coronary artery disease. So, why does this indication or patient population make the most sense as the next step?
Yeah, I mean, if you look at the aggregate of all the work that's been done in ASCVD, this goes back to Novartis's canakinumab trial, or you could argue even going back to some of the trials with lipid-lowering drugs. You look at some of the cardiovascular outcome trials for GLP-1 agonists, I think the common denominators are, like, sure, coronary artery disease is probably the subgroup, it's the most important, the biggest subgroup, but also the ones where your efficacy seems to be most predictable. I think that has to do with sort of the makeup of those atherosclerotic plaques and how modifiable they are. It was interesting to see, and we've heard this a few times from investors, why not go after peripheral artery disease? In ZEUS, that was literally the worst of all subgroups.
It was a small subgroup, and the hazard ratio, and I'm not saying it was statistically significantly, but the reported hazard ratio there, I think, was 1.3. That makes 0.97 look really good, right? It just tells you there are just subtypes of ASCVD that are probably a little bit too messy to think you can be successful in an outcomes trial.
You're using coronary artery imaging and the fat attenuation index.
Can you talk a bit about those and how important those are in terms of kind of identifying patients who have the type of inflammation that you're looking for?
Yeah, so we believe this will be very important, at the very least, in sort of identifying patients with active ongoing inflammation in plaques. This is essentially how the method has been established. I mean, the sort of standard of care CTs, but like sort of a different way of analyzing those images. In a great study, I think like 40,000 patients essentially establishing that when you're positive for FAI, you have a tremendously increased risk of mortality. I think it was like a close to 30-fold increase. It hasn't really been used yet to assess efficacy. There's a few trials that are ongoing that will sort of tell us on how much you can actually also lower FAI and predict future cardiovascular outcome.
But for finding the truly inflamed patients that carry sort of residual risk, even in sort of an optimal sort of lipid-lowering setting, I think this will be a game-changer.
I'm just curious, is this something that could be rolled out on a larger scale, this type of imaging to identify patients, or will we still rely on hsCRP?
No, I mean, I think this will pretty much become a standard of care for coronary artery disease. Now, hsCRP for therapeutic response, I think, will remain very important because again, we still have to establish that for FAI, and how much that actually predicts outcome. I think for hsCRP, despite ZEUS's failure, we have that, right? Because let's not forget, like CANTOS as the trial for canakinumab showed that correlation, right? I think for hsCRP, it can be very predictive if you go after the right node in the pathway. IL-6 wasn't the right node in the pathway, and for hsCRP, it's extremely easy to measure wherever you live in the world. So, I think this will remain an important assay, but you do have to sort of establish that correlation, of course.
So, for the GFORCE-2 study, remind us, what are the timelines for this study, and what do you really need to show for that readout?
Yeah, I mean, timelines are fairly simple. I think we've guided to a start first half of next year. Obviously, we're trying to get this off the ground as early as possible next year. The outcome here, again, this will be six months of treatment, right? It won't be an outcomes trial. What we really want to see is sort of an established correlation between that fat attenuation index and some of the more proximal biomarkers we've talked about, right? Like DAMPs, whether there is a good correlation with hsCRP. To be determined, because as I said, sure, there's other things that can lead to CRP increases, right? I think this will be very telling at the end of the day. I think if we then also see a reduction in the fat attenuation index after six months, even better.
We've also mentioned that we're looking into genetics. There are some interesting results, and we had a little bit of that in our disclosure around SNPs and NLRP3 and increased biomarkers indicating increased inflammation in those patients. This is really the correlations you want to establish, right? FAI, proximal biomarkers, and how all of this correlates to NLRP3 genetics.
Okay, great. You have a couple of other indications, I think, with this asset, gout and HS. Could you maybe talk about those trials and the timelines there? I think we might be getting the gout trial readout ahead of the CAD readout. So, what can you learn from that one that could inform the CAD?
Yeah, I mean, gout, sort of somewhat different, although interestingly on a pathology signaling point of view, very similar, right? Both gout and ASCVD are induced, or the pathway is induced by crystals, here it's MSU crystals. So, urate crystals that form in those patients and then trigger the pathway and then inflammation. The upside on gout, of course, is sure there's a fairly easy clinical readout even in the phase II. It's avoidance of flares. Our phase II here is going to be fairly simple, small, 60 patients to those cohorts, essentially looking to prevent recurrent flares after management of an acute flare. There's lots of proof of concept for the pathway in gout, including canakinumab. But even better, there is a small molecule that's being used, so it has lots of side effects with colchicine.
Hopefully when this reads out second half of next year, it'll be positive and sort of pave a path into really substantial broad use of 8102 in the future. Obviously, have to do a phase III trial there next. For HS, this will likely be the third trial to start. Guidance is also first half of next year, but it will likely be after GFORCE-2. Obviously, a space that's becoming a little bit more cloudy as well, right, with some of the recent, not necessarily negative readouts, but readouts that weren't as positive as hoped for, mostly because of over-performing placebo arms, but then also interesting drops in activity for the active arm between phase IIs and phase IIIs. Some interesting observations there also. I mean, we've looked at a lot of the data over the last five years systematically.
Many of the phase II actually had shown inverse dose responses, which we're trying to understand. Some more work for us to do in preparing that trial before we can kick it off.
Very interesting. Why don't we move to your VAV1 degrader then, which is 6160, which you have partnered with Novartis. Maybe we can start with why is VAV1 an exciting target? It seems like you're one of the only companies pursuing this.
Yeah, so one, we are just super excited about. It does fall into this category of absolutely undruggable targets, proteins. No one has ever been able to find a ligand. No one has ever been able to find an inhibitor, and we know many pharma companies tried for a long time, and that actually includes Novartis. We have this wonderful molecule, 6160. We used it a lot to understand what VAV1 actually does, and we are degrading it. We will work best. Turns out it is really important in tonic signaling in autoimmune disease between T and B cells. So, open up a lot of future development opportunity in any autoimmune disease that is either T cell driven or T cell, B cell driven. Obviously, with the two trials that are now disclosed from Novartis, that is exactly sort of that type of biology.
Great. In terms of Novartis's initial indication choices, why do you think they prioritized Sjögren's and PsA, and what are some other indications that you think make sense?
Yeah, so as I just said, anything that is T cell or B cell mediated, pre-clinically, for those who have looked at our corporate decks in the past, we have worked in IBD, could make a ton of sense to work there on. We did a rheumatoid arthritis model. In general, anything arthritis would be great indications, and hence probably the psoriatic arthritis trial. Other things, Novartis will not stop at those two trials, right? Our guidance is Novartis planning to start several additional trials. So, I do not even think they have prioritized Sjögren's. It was just like, here is a range of indications. Let us just go full steam ahead, and whatever starts first just starts first, because it was the quickest path to initiating a trial. So we are super excited. As you might know, we actually own 30% of the profit, also of the losses in the U.S.
From a commercial value creation opportunity for us, still a huge product. It is not a simple license with future royalties. It is really a collaboration where we feel still that sense of ownership and obviously benefiting from the fact that for now we do not have to pay anything until phase III, for development. So Novartis is essentially helping us to de-risk some of these indications.
At what point do you need to make that decision about the profit share?
It is not an opt-in, right?
Okay.
It is essentially an opt-out. We are in until we decide it is too much. All that said, the 30% profit share does not mean we have to pay 30% of future development costs. We believe it is fairly manageable, but I am sure if there was a need, we could always opt out and revert to a more conventional structure.
Okay. I will pause here and see if there are any questions from the audience. Would you like to spend the last few minutes then talking about your GSPT1 program?
Definitely, and in general, I mean, for sure, VAV1 and NEK7 are massive, right? The oncology always seems like a little bit of a side gig. We really like that setup of being able to work across multiple disease areas. I think 2359, our GSPT1 degrader, has generated great data in prostate cancer. It's a small data set on just five patients for now. We have an update coming that has actually one additional patient. But a great data set with 100% PSA responses, and literally each patient had a tumor shrinkage, two of them to the degree of a PR. I think this is an asset that over time can move into multiple different combination strategies in prostate cancer, which we like.
As you know, we also have a CDK2 and a cyclin E1 degrader program that are now approaching IND. CDK2 will likely go first next year, and then followed by cyclin E1. Again, at a time where many of the CDK2 inhibitors out there are turning out to be not as selective as advertised and too toxic. We think these will create great opportunities for us. Kind of coming back to the beginning and the pitch of molecular glue degraders, I think what we have learned over the last seven years is that not only can we go after completely undruggable things, we can make these degraders also exquisitely selective, right? Our CDK2 degrader degrades CDK2 and nothing else, no other kinase, no other protein. I know because I can measure that on a cellular level in proteomics.
But this isn't like a biochemical assay array of 20 different kinases, and I'm guessing. We really know about our selectivity, and that's really created unbelievably cool safety packages, at least pre-clinically. Whether we apply this in I&I or in oncology doesn't really matter.
Great. Well, I think we can leave it there. Thank you so much for-
Sounds great, yeah.
being here with us, and thank you everyone for joining.
Super. Thanks for the invite.